amikacin + linezolid + vancomycin

This is a combination of three antibiotics—amikacin, linezolid, and vancomycin—used together for the treatment of severe or multidrug-resistant bacterial infections. Each component has a distinct mechanism of action:

• Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing misreading of mRNA in bacteria.
• Linezolid is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex.
• Vancomycin is a glycopeptide antibiotic that inhibits cell wall biosynthesis by binding to D-Ala-D-Ala termini in peptidoglycan precursors.

The combination may be considered for difficult-to-treat infections caused by resistant Gram-positive organisms (such as MRSA or VRE) or mixed infections where broad-spectrum coverage is needed. Synergistic effects have been observed between some pairs (e.g., amikacin with vancomycin, linezolid with aminoglycosides), but antagonism has also been reported between vancomycin and linezolid in certain strains. The use of all three drugs together would be reserved for highly resistant cases under specialist supervision.